---
title: "Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292896913.md"
description: "On July 16, 2026, Gain Therapeutics, Inc. (Nasdaq: GANX) based in Bethesda, Md., a biotech firm advancing allosteric small molecule therapies, issued a shareholder letter from CEO Gene Mack. This communication outlines the company's progress in the clinical-stage development of innovative therapies."
datetime: "2026-07-16T11:03:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292896913.md)
  - [en](https://longbridge.com/en/news/292896913.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292896913.md)
generator: "portal-rs"
---

# Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

On July 16, 2026, Gain Therapeutics, Inc. (Nasdaq: GANX) based in Bethesda, Md., a biotech firm advancing allosteric small molecule therapies, issued a shareholder letter from CEO Gene Mack. This communication outlines the company's progress in the clinical-stage development of innovative therapies.

### Related Stocks

- [GANX.US](https://longbridge.com/en/quote/GANX.US.md)

## Related News & Research

- [Gain Therapeutics joins H.C. Wainwright Global Investment Conference for investor meetings](https://longbridge.com/en/news/296901905.md)
- [13:27 ETPatients Representing the Power of Advanced Therapies to Take Center Stage at Emily Whitehead Foundation's 2026 Believe Ball](https://longbridge.com/en/news/297074492.md)
- [Can Komzifti's Early Adoption Support Kura Oncology's Next Phase Of Growth?](https://longbridge.com/en/news/296928079.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [Wills Group Celebrates 100 Years with $500,000 in Grants to Southern Maryland Nonprofits](https://longbridge.com/en/news/296913441.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**